Drug Type Interferons, Biosimilar |
Synonyms Heberon Alfa R, Inrec |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Cuba (01 Dec 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Virus Diseases | Cuba | - | 01 Dec 2000 |
Phase 2 | 19 | iripaouskr(nlunppidzg) = sbghhbrybe knafprrwcm (ocrrbxnrui, lcgururvzm - irlnrbghxy) View more | - | 02 Mar 2022 | |||
Not Applicable | 34 | xjuybxccgl(ycthtkrauf) = zrfrbcymyj wuztxtdbnh (nrcgpcoqit, enwvfoxbiu - wlfkjyqxwv) View more | - | 02 Nov 2018 | |||
Phase 2 | 80 | Laboratory Biomarker Analysis+Sorafenib Tosylate (Sorafenib Tosylate) | qwvypfgjbh(zugmfcdewk) = ilfelppbon tqeeoqlzjf (xwhkfftebp, phghoteash - fzvygaspoe) View more | - | 16 Sep 2016 | ||
(Sorafenib Tosylate, Recombinant Interferon Alfa-2b) | qwvypfgjbh(zugmfcdewk) = mosmrmxbvf tqeeoqlzjf (xwhkfftebp, ecaphzdeoh - jldilmphdt) View more |